← All trials
NCT07260513
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2030
- First posted
- Dec 3, 2025
- Last posted
- Dec 3, 2025
- Enrollment
- 126
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Genhouse Bio Co., Ltd.Lead sponsor
- Fudan UniversityCollaborator
- GCP-Service International Ltd. & Co. KGCollaborator
- Government of ChinaCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Suzhou Genhouse Bio Co., Ltd.Official
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.